PEPTIDE GUIDE

What Is Prostamax?

Prostamax is the name used for an experimental four-amino-acid peptide generally identified as lysine-glutamic acid-aspartic acid-proline, abbreviated KEDP. It belongs to the Russian short-peptide bioregulator programme and is marketed with prostate-related language.

Its evidence does not match the breadth of those claims. One paper placed Prostamax into organotypic prostate-tissue cultures from young and old rats. Several other papers exposed cultured human blood cells to the peptide and measured chromatin structure. No published trial was identified in which men received synthetic KEDP and had urinary symptoms, prostate size, urine flow, prostatitis or cancer outcomes measured.

Prostamax is also different from prostate-derived polypeptide extracts such as Prostatilen and Vitaprost. Clinical reports about those mixtures cannot establish that KEDP has the same effects.

Research statusLaboratory research only; no published human treatment trial identified
Compound typeExperimental four-amino-acid peptide
Human evidenceHuman cells studied outside the body; no treatment trial
ApprovalNot approved by FDA, MHRA or EMA
Last reviewedOctober 2026
THE SHORT ANSWER

Prostamax is a synthetic tetrapeptide usually reported as KEDP. Removed rat prostate tissue showed increased outgrowth after exposure in one multi-peptide experiment. Cultured human lymphocytes showed changes in chromatin organisation, ribosomal-gene markers and sister-chromatid exchange. Those blood-cell findings are not prostate outcomes, and one of them raises a genomic-stability question rather than providing simple reassurance. No human treatment trial of synthetic Prostamax was identified. It has not been shown to improve benign prostatic enlargement, chronic prostatitis, urinary symptoms, sexual function or prostate cancer.

What is Prostamax made from?

The reported sequence is:

`Lys-Glu-Asp-Pro (KEDP)`

These names refer to lysine, glutamic acid, aspartic acid and proline. A tetrapeptide contains four amino-acid residues connected by three peptide bonds. Proline has a ring-shaped side chain that restricts movement of the peptide backbone and may influence susceptibility to enzymes.

The name-to-sequence connection appears in the originating literature, including a chromosome study that explicitly describes Prostamax as Lys-Glu-Asp-Pro. Even so, a marketed name does not verify the contents of a particular product. Identity requires sequence-sensitive analytical testing.

Why is Prostamax associated with the prostate?

The short-peptide programme began with polypeptide fractions isolated from animal organs and later proposed synthetic sequences associated with particular tissues. Prostamax was assigned to prostate research in this framework.

The prostate is a gland below the bladder that contributes fluid to semen and surrounds the first part of the urethra, the tube carrying urine out of the body. Growth of prostate tissue can narrow that passage and cause lower urinary tract symptoms.

An organ-associated name does not show that intact KEDP travels selectively to prostate cells. A targeting claim requires distribution measurements, cell uptake and evidence of interaction with a defined prostate target. No human pharmacokinetic study provides those data.

What did the rat prostate-tissue experiment find?

A 2006 paper tested four peptides in organotypic cultures from young and old rats. Cardiogen was paired with heart tissue, Bronchogen with lung, Pancragen with pancreas and Prostamax with prostate.

At a reported laboratory concentration of 0.05 nanograms per millilitre, each peptide stimulated outgrowth in the tissue associated with its name compared with untreated explants. An explant is a small piece of tissue kept alive outside the body.

Outgrowth is a broad measure that can reflect movement, proliferation or extension of different cell types. The prostate contains glandular epithelial cells, smooth muscle, fibroblasts, blood vessels, nerves and immune cells. The abstract does not establish which population expanded or whether that expansion would help a diseased prostate.

This ambiguity is especially important because excess prostate growth contributes to benign prostatic hyperplasia. Stimulating growth cannot be assumed to relieve a condition partly characterised by enlargement.

Does tissue outgrowth mean prostate repair?

No. Repair requires restoration of appropriate structure and function after injury. An enlarged growth zone around removed tissue does not show normal glandular organisation, reduced inflammation or improved urinary flow.

Cell proliferation may be useful after some injuries, but it can also worsen benign enlargement or support abnormal cells. Researchers would need to identify the responding cells, examine tissue architecture and show that proliferation remains controlled.

A useful animal study would measure prostate volume, inflammation, urethral obstruction, bladder changes and urination. No published living-animal Prostamax study was identified with those outcomes.

What did the lymphocyte calorimetry study show?

A 2004 paper exposed cultured human lymphocytes to Prostamax and used differential scanning calorimetry. Lymphocytes are white blood cells involved in immunity. Calorimetry measures heat absorbed as cellular material changes structure at increasing temperatures.

The researchers reported shifts in thermal transitions attributed to chromatin and interpreted them as partial relaxation of tightly packed fibres. Chromatin is DNA packaged with proteins inside the nucleus. Its degree of compaction helps regulate access to genes.

These are physical measurements in blood cells outside the body. They do not show that Prostamax reaches prostate tissue, selects a helpful gene or improves a urological outcome. The interpretation also depends on assigning broad heat transitions to particular levels of chromatin organisation.

What was found in leukocytes from older people?

Another study cultured leukocytes from people aged 75 to 88 with Vilon, Epithalon, Livagen, Prostamax or Cortagen. Leukocytes are the wider group of white blood cells that includes lymphocytes.

The researchers examined activity of ribosomal genes, general heterochromatin melting and structural chromosome regions. Ribosomal genes help produce the cellular machinery that makes proteins. The paper reported that Prostamax, Epithalon and Livagen decondensed a region near the centre of chromosome 1.

This provides evidence of a laboratory chromatin response. It does not demonstrate rejuvenation. Chromatin condensation is tightly regulated, and opening a region is not automatically beneficial. The study also did not measure prostate cells or clinical health.

What is sister-chromatid exchange, and why does it matter?

Before a cell divides, each chromosome is copied into two sister chromatids. Sister-chromatid exchange occurs when corresponding DNA segments swap between those copies. A higher frequency can indicate increased DNA damage, replication stress or repair activity and is often used as a marker of genomic instability.

A 2012 Prostamax study used lymphocytes from people aged 75 to 86. After exposure, the reported frequency rose from 5.9 to 12.0 exchanges per cell. The study also reported more silver-positive nucleolar organiser regions, from 0.95 to 2.5 per cell, and changes in heterochromatin around chromosomes 1 and 9.

The authors interpreted the overall pattern as chromatin decondensation and release of repressed genes. Yet a doubling of sister-chromatid exchange is not straightforward evidence of protection. It creates a safety question about DNA stability that needs replication and mechanistic explanation.

This experiment should not be reframed as proof that Prostamax repairs genetic ageing. It shows that cultured cells changed, including a marker that can be associated with genomic stress.

What are nucleolar organiser regions?

Nucleolar organiser regions are chromosome segments containing repeated genes for ribosomal RNA. Cells use ribosomal RNA to build ribosomes, which translate genetic instructions into proteins. Silver staining can identify active regions and is often abbreviated AgNOR.

More AgNORs can accompany increased ribosomal-gene activity, but they are not a universal sign of healthier cells. Rapidly growing cells, including some cancers, can also show increased nucleolar activity. Meaning depends on cell type, context and accompanying measurements.

The Prostamax study measured AgNORs in cultured blood cells. It did not demonstrate more useful protein production in prostate tissue or improved function in men.

What did the metal-ion experiment examine?

A later microcalorimetry paper studied Prostamax alongside copper and cadmium ions in cultured human lymphocytes. Cadmium can damage cells and alter chromatin, while copper is essential at normal concentrations but can be harmful in excess.

The experiment asked whether Prostamax changed thermal features of chromatin alone or during metal exposure. This is a specialised laboratory model of structural response. It cannot establish protection from environmental metal exposure in people.

It also adds no direct evidence for benign prostatic hyperplasia, prostatitis or cancer. The use of human cells does not make an ex vivo assay a human treatment trial.

Was Prostamax studied in human prostate cells?

A 2010 paper is sometimes pulled into the Prostamax evidence base because it examined ageing cultures of human prostate fibroblasts. However, the abstract identifies peptides T-32, T-38 and Cardiogen, not Prostamax or KEDP.

The study reported changes in CXCL12, WEDC1 and ghrelin, with T-38 described as the most active. T-38 is generally identified as KED, a three-amino-acid sequence, not KEDP. Adding proline produces a chemically different peptide.

Results for T-38 cannot be assigned to Prostamax. This identity boundary leaves the rat explant experiment as the direct prostate-tissue evidence for the named compound.

Is Prostamax the same as Prostatilen or Vitaprost?

No. Prostamax is presented as a defined synthetic tetrapeptide. Prostatilen and Vitaprost are prostate-derived polypeptide preparations containing mixtures of biological material.

Some clinical publications examine those extracts in chronic prostatitis, benign prostatic hyperplasia or sexual-function contexts. Even if a mixture produces an effect, the result does not identify KEDP as the active component. Other peptides or non-peptide constituents could be responsible, and manufacturing differs.

Evidence transfer requires a bridging study comparing chemically characterised products. Without one, the clinical extract literature belongs to the extract, not Prostamax.

Does Prostamax treat benign prostatic hyperplasia?

No clinical trial has shown that it does. Benign prostatic hyperplasia, abbreviated BPH, is non-cancerous enlargement that becomes common with age. Symptoms can include weak urine flow, hesitancy, urgency, frequent urination and waking at night to urinate.

Prostate size is only part of the problem. Smooth-muscle tone, bladder function and inflammation can also affect symptoms. A useful study would measure the International Prostate Symptom Score, maximum urine-flow rate, urine remaining after voiding and prostate volume.

None of these outcomes has been reported in men receiving synthetic KEDP. Tissue outgrowth is not evidence of symptom relief and could raise the opposite biological concern.

Does Prostamax treat chronic prostatitis?

No reliable evidence supports that claim. Chronic prostatitis and chronic pelvic pain syndrome can involve pelvic pain, urinary symptoms and sexual difficulties. Causes vary, and many cases do not involve an ongoing bacterial infection.

A trial would need a clear diagnostic definition, validated symptom scores, appropriate comparison and follow-up. Clinical findings for prostate-derived extracts cannot be reassigned to KEDP. No such Prostamax trial was identified.

Does Prostamax prevent or treat prostate cancer?

No. The compound has not been shown to prevent, slow or treat prostate cancer. The direct literature does not provide a prostate-cancer cell experiment, animal tumour model or patient trial.

Chromatin decondensation and increased sister-chromatid exchange do not support an anti-cancer claim. Prostate cancer involves varied changes in androgen signalling, tumour-suppressor genes, DNA repair and other pathways. A general change in cultured lymphocyte chromatin cannot predict tumour control.

Men with urinary symptoms or an abnormal prostate-specific antigen result need appropriate medical assessment. Prostate-specific antigen, abbreviated PSA, is a protein measured in blood that can rise for several benign and malignant reasons.

Has Prostamax been tested in humans?

Human-derived cells have been studied outside the body, but no published study was identified in which a person received synthetic Prostamax as treatment. This difference is crucial.

An ex vivo study removes cells, exposes them under controlled laboratory conditions and measures a response. It cannot test absorption, distribution, metabolism, adverse effects or symptoms in the donor.

There is no Phase I programme establishing initial safety and pharmacokinetics. There is also no controlled evidence for urinary flow, pain, infection recurrence, sexual function, gland size, PSA or cancer outcomes.

What would credible prostate evidence require?

Development would begin with an analytically confirmed KEDP product and pharmacokinetic studies showing whether intact peptide reaches blood and prostate tissue. Researchers would need to establish which prostate cell type responds and whether the effect is helpful rather than proliferative.

For BPH, a randomised trial would compare Prostamax with placebo or established care and measure validated symptoms, flow and retention. For chronic pelvic pain, pain and quality of life would be central. A cancer claim would require a separate programme focused on tumour biology, progression and survival.

Random allocation creates comparable groups. Masking limits expectation and assessment bias. Prespecified outcomes reduce selective reporting. Adequate duration is needed because prostate conditions and adverse effects may evolve slowly.

No part of this clinical chain has been completed for Prostamax.

Is direct DNA or chromatin regulation established?

The lymphocyte experiments show thermal and staining changes consistent with altered chromatin organisation. They do not identify a unique KEDP receptor or prove direct binding to a specific human gene.

An in vitro review reported that KEDP and other charged peptides can affect the melting temperature and stability of DNA. Melting temperature is the point at which the two DNA strands separate under experimental conditions. This physical interaction does not demonstrate selective gene regulation in a living prostate.

A mechanism would need direct binding measurements, sequence controls, cellular target engagement and a connection to a useful functional outcome. The current record stops well before that point.

Could Prostamax be absorbed orally?

Computational work has modelled KEDP as a possible ligand for intestinal peptide transporters. A ligand is a molecule predicted or shown to interact with a binding site. Transporter modelling does not prove absorption in an animal or person.

Peptides can be split by digestive and blood enzymes. Even if some intact KEDP entered circulation, researchers would still need to measure its concentration, half-life and prostate exposure. No published human bioavailability study supplies those data.

What is known about safety?

There is no adequate human safety record. The cell papers were not designed to detect whole-body adverse effects. They cannot assess allergy, blood pressure, liver and kidney effects, fertility, medicine interactions or delayed toxicity.

The increased sister-chromatid exchange reported in cultured cells deserves caution. It does not prove that Prostamax damages DNA in people, because the exposure occurred outside the body and needs replication. It does prevent a confident claim that chromatin activation is inherently protective.

Proliferation is another unresolved issue. A programme centred on prostate tissue needs to distinguish repair from unwanted growth, BPH progression and tumour support. No long-term carcinogenicity study was identified.

Product quality adds risk. A label cannot prove sequence, content, sterility or freedom from bacterial endotoxins. A purity percentage does not establish pharmaceutical quality or clinical safety.

How is Prostamax synthesised and checked?

KEDP can be assembled by solid-phase peptide synthesis. Protected amino acids are joined in the required order while the chain remains attached to a resin. Temporary protecting groups limit unintended reactions. The finished chain is released, deprotected and purified.

Mass spectrometry can test molecular mass, and fragmentation can add sequence information. Chromatography separates the desired tetrapeptide from shorter chains and related impurities. Additional analysis may examine content, counterions, water, residual solvents and stability.

Material for regulated sterile research would also require batch consistency, potency, particle, sterility and endotoxin controls. This is a non-procedural overview, not a production guide.

How was Prostamax developed?

PeriodDevelopment
1970s onwardSoviet and Russian programmes investigated organ-derived peptide preparations
Later developmentKEDP was assigned to prostate-associated short-peptide research
2003 to 2004Cultured leukocyte and lymphocyte studies reported chromatin changes
2006An organotypic study reported outgrowth in removed rat prostate tissue
2009 to 2012Further lymphocyte studies examined metals, heterochromatin and chromosome markers
Through October 2026No living-animal prostate study or human treatment trial was identified

Is Prostamax approved?

No. Prostamax is not approved by the United States Food and Drug Administration, the United Kingdom Medicines and Healthcare products Regulatory Agency or the European Medicines Agency.

How strong is the evidence overall?

QuestionBest available evidenceDefensible conclusion
Does Prostamax affect removed rat prostate tissue?One organotypic multi-peptide studyOutgrowth increased under one condition
Does it alter cultured human cells?Several lymphocyte chromatin studiesStructural and chromosome markers changed
Does it target the prostate in a living body?No distribution studyNot established
Does it improve BPH or prostatitis?No KEDP treatment trialUnknown
Does it prevent or treat prostate cancer?No relevant direct studyNot established
Is it safe in people?No human exposure studyUnknown
Is it approved?No FDA, MHRA or EMA approvalNo
FREQUENTLY ASKED QUESTIONS

Frequently asked questions

What is Prostamax?

It is an experimental tetrapeptide associated with prostate and chromatin research.

What is its sequence?

It is usually reported as Lys-Glu-Asp-Pro, abbreviated KEDP.

Does Prostamax shrink the prostate?

No human evidence shows a reduction in prostate size.

Does it improve urinary flow?

No clinical trial has measured or demonstrated that outcome.

Is Prostamax the same as Prostatilen?

No. Prostamax is a defined synthetic peptide, while Prostatilen is an animal-prostate-derived mixture.

Does Prostamax treat prostatitis?

No treatment trial of synthetic KEDP has established benefit.

Does it treat prostate cancer?

No. There is no supporting direct cancer evidence.

Has Prostamax been tested in people?

Human cells have been studied outside the body, but no human treatment study was identified.

Is Prostamax known to be safe?

No adequate human safety profile exists.

Is Prostamax approved?

It is not approved by the FDA, MHRA or EMA.

Research reviewed through October 2026.